Broadfin Capital Upped By $2.51 Million Its Juno Therapeutics (JUNO) Position; Electron Capital Partners Has Boosted Albemarle (ALB) Position By $424,410

November 4, 2017 - By Louis Casey

Electron Capital Partners Llc increased Albemarle Corp (ALB) stake by 4.92% reported in 2017Q2 SEC filing. Electron Capital Partners Llc acquired 4,042 shares as Albemarle Corp (ALB)’s stock rose 20.02%. The Electron Capital Partners Llc holds 86,149 shares with $9.09 million value, up from 82,107 last quarter. Albemarle Corp now has $15.47 billion valuation. The stock increased 2.30% or $3.15 on November 3, reaching $140.04. About 1.40 million shares traded or 9.38% up from the average. Albemarle Corporation (NYSE:ALB) has risen 45.60% since November 4, 2016 and is uptrending. It has outperformed by 28.90% the S&P500.

Broadfin Capital Llc increased Juno Therapeutics Inc (JUNO) stake by 49.17% reported in 2017Q2 SEC filing. Broadfin Capital Llc acquired 86,400 shares as Juno Therapeutics Inc (JUNO)’s stock rose 2.20%. The Broadfin Capital Llc holds 262,100 shares with $7.83M value, up from 175,700 last quarter. Juno Therapeutics Inc now has $6.68 billion valuation. The stock decreased 2.39% or $1.43 on November 3, reaching $58.48. About 5.48M shares traded or 136.21% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 39.85% since November 4, 2016 and is downtrending. It has underperformed by 56.55% the S&P500.

Investors sentiment increased to 1.25 in Q2 2017. Its up 0.02, from 1.23 in 2017Q1. It improved, as 32 investors sold ALB shares while 163 reduced holdings. 76 funds opened positions while 168 raised stakes. 90.94 million shares or 3.05% less from 93.80 million shares in 2017Q1 were reported. Vanguard Group Incorporated owns 12.50 million shares. 7,157 are held by Liberty Mutual Group Asset. Ig Invest Mgmt holds 0.04% of its portfolio in Albemarle Corporation (NYSE:ALB) for 68,215 shares. Luminus Ltd Llc holds 0.21% or 95,569 shares in its portfolio. Jennison Assocs Limited Company reported 0.72% in Albemarle Corporation (NYSE:ALB). Lone Pine Cap Ltd Co holds 0.62% in Albemarle Corporation (NYSE:ALB) or 1.16M shares. Davenport & Ltd reported 0% in Albemarle Corporation (NYSE:ALB). Public Sector Pension Invest Board holds 12,400 shares or 0.01% of its portfolio. Principal Financial owns 544,274 shares. Quantbot Techs Lp holds 0.2% in Albemarle Corporation (NYSE:ALB) or 20,593 shares. First Citizens National Bank & Trust And Tru Communication holds 11,100 shares. State Board Of Administration Of Florida Retirement stated it has 0.05% of its portfolio in Albemarle Corporation (NYSE:ALB). Westpac holds 0% or 6,745 shares in its portfolio. Cornerstone Advsr has 0.1% invested in Albemarle Corporation (NYSE:ALB). Dnb Asset As holds 0% of its portfolio in Albemarle Corporation (NYSE:ALB) for 10,311 shares.

Since June 19, 2017, it had 0 buys, and 2 insider sales for $3.24 million activity. Maine Douglas L had sold 10,000 shares worth $1.08M. Shares for $2.16M were sold by NARWOLD KAREN G on Monday, June 19.

Among 20 analysts covering Albemarle Corporation (NYSE:ALB), 12 have Buy rating, 0 Sell and 8 Hold. Therefore 60% are positive. Albemarle Corporation had 54 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, April 5 by Jefferies. As per Thursday, May 12, the company rating was maintained by Deutsche Bank. The stock of Albemarle Corporation (NYSE:ALB) earned “Outperform” rating by RBC Capital Markets on Wednesday, March 1. As per Friday, September 1, the company rating was maintained by KeyBanc Capital Markets. The stock of Albemarle Corporation (NYSE:ALB) has “Buy” rating given on Monday, August 21 by Jefferies. The stock of Albemarle Corporation (NYSE:ALB) has “Buy” rating given on Monday, October 23 by Jefferies. RBC Capital Markets maintained Albemarle Corporation (NYSE:ALB) rating on Wednesday, April 19. RBC Capital Markets has “Buy” rating and $132 target. The firm has “Neutral” rating given on Thursday, March 10 by Seaport Global. RBC Capital Markets initiated the stock with “Outperform” rating in Thursday, February 23 report. As per Wednesday, November 11, the company rating was initiated by UBS.

Broadfin Capital Llc decreased Avadel Pharmaceuticals Plc stake by 261,000 shares to 4.13 million valued at $45.59 million in 2017Q2. It also reduced Strongbridge Biopharma Plc stake by 109,778 shares and now owns 2.87 million shares. Endologix Inc (NASDAQ:ELGX) was reduced too.

Investors sentiment increased to 1.33 in 2017 Q2. Its up 0.22, from 1.11 in 2017Q1. It improved, as 21 investors sold JUNO shares while 40 reduced holdings. 38 funds opened positions while 43 raised stakes. 53.50 million shares or 13.76% more from 47.03 million shares in 2017Q1 were reported. Millennium Management Ltd Co, a New York-based fund reported 428,968 shares. D E Shaw invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO). Us Fincl Bank De reported 0.01% stake. Dekabank Deutsche Girozentrale accumulated 48,400 shares. Rock Springs Capital Mgmt Lp holds 225,000 shares. First Trust Advisors Limited Partnership has invested 0.1% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Voya Inv Mngmt Ltd Liability Com holds 0% in Juno Therapeutics Inc (NASDAQ:JUNO) or 17,799 shares. Brighton Jones Ltd Liability holds 0.04% in Juno Therapeutics Inc (NASDAQ:JUNO) or 8,684 shares. Orbimed Advisors Limited Co stated it has 915,208 shares or 0.29% of all its holdings. Credit Suisse Ag reported 210,051 shares or 0.01% of all its holdings. 351 are owned by Bessemer Group Inc Inc. 21,475 were accumulated by Fairfield Bush &. Northwestern Mutual Wealth Mgmt Company accumulated 800 shares. Pnc Financial Ser Gp Inc invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). 382,631 were reported by Northern Corporation.

Among 16 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 10 have Buy rating, 1 Sell and 5 Hold. Therefore 63% are positive. Juno Therapeutics Inc had 43 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Hold” rating by Standpoint Research on Thursday, October 29. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Outperform” rating by Wedbush on Tuesday, August 29. Suntrust Robinson downgraded the stock to “Hold” rating in Friday, November 25 report. On Monday, August 24 the stock rating was initiated by Standpoint Research with “Buy”. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Hold” rating by SunTrust on Friday, November 25. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Reduce” rating given on Thursday, August 31 by Standpoint Research. Morgan Stanley maintained Juno Therapeutics Inc (NASDAQ:JUNO) on Friday, October 6 with “Equal-Weight” rating. Raymond James upgraded Juno Therapeutics Inc (NASDAQ:JUNO) rating on Tuesday, August 29. Raymond James has “Buy” rating and $45.0 target. The company was initiated on Friday, January 29 by Suntrust Robinson. The firm has “Outperform” rating by Wells Fargo given on Wednesday, February 22.